A clinical trial is a research study that is designed to test the effectiveness of new medical treatments or other medical interventions. Each study is designed to answer scientific questions and to find better ways to treat individuals with a specific disease.

All clinical trials conducted at EVMS are approved by the FDA and by the EVMS Institutional Review Board (IRB). EVMS Internal Medicine's clinical trials are listed by division below.

Strelitz Diabetes Center

Primary Investigator: Elias S. Siraj, MD

Summary: The purpose of this study is to evaluate the effects of dapagliflozin as compared with placebo on heart failure disease-specific biomarkers, symptoms, health status and quality of life in patients with chronic heart failure with preserved systolic function.

Point of contact: Henri Parson, PhD, or Norine Kuhn

Start date: 9/7/2017

You may be eligible to participate in this study if you:

  • Have been diagnosed with chronic heart failure
  • Are at least 18 years old

Primary Investigator: Aaron Vinik, MD, PhD, FCP, MACP, FACE

Summary: The primary objective of this study is to determine if oral Topiramate slows progression of Cryptogenic Sensory Peripheral Neuropathy (CSPN) in subjects with Metabolic Syndrome and pre-diabetes.

Point of contact: Carolina Casellini, MD, and Henri Parson, PhD

Start date: 03/27/2018

You may be eligible to participate in this study if you are:

  • Are at least 18 years old
  • Have signs of metabolic disease including abdominal obesity, pre-diabetes, high blood pressure and abnormal cholesterol/lipids
  • Have numbness and tingling on the feet

Primary Investigator: Elias S. Siraj, MD

Summary: The purpose of this study is to determine if semaglutide may reduce the risk of cardiovascular events (e.g, stroke, heart attack) in patients that are overweight or obese and have a history of cardiovascular disease.

Point of contact: Henri Parson, PhD, or Norine Kuhn

Start date: 12/1/2018

You may be eligible to participate in this study if you are:

  • Diagnosed with cardiovascular disease
  • Overweight or obese
  • At least 18 years old

Primary Investigator: Aaron Vinik, MD, PhD, FCP, MACP, FACE

Summary: This study is designed to better understand factors that impact or lead to the perception of fatigue in subjects diagnosed with either type 1 (T1DM) or type 2 diabetes mellitus (T2DM) who are who are between 18-80.

Point of contact: Carolina Casellini, MD and Henri Parson, PhD

Start date: 01/31/2017

You may be eligible to participate in this study if you are:

  • Are at least 18 years old
  • Have type 1 or type 2 diabetes

Glennan Center for Geriatrics and Gerontology

Sponsor: Private organization working in conjunction with researchers from Old Dominion University (ODU).

Summary: To determine whether THC-free CBD oil can help reduce the frequency and severity of agitation among participants with Alzheimer’s Disease (AD), or AD mixed with another type of dementia.

Point of Contact: David Elkins, MS, Research Coordinator, 757.446.5675

Additional ContactGlennanCenterResearchTrials@evms.edu 

To be eligible, participants must be:

  • Women and men over the age of 50
  • Have a diagnosis of dementia due to AD or mixed AD with another type of dementia.
  • Experience frequent agitation. Common symptoms include:
    • Restlessness; pacing back and forth
    • Feeling anxious
    • Sleeplessness
    • Aggression
    • Yelling
    • Attempting to hit or kick.
  • Have a caregiver who spends at least four hours per day with the participant and supervises their care, is willing to accompany the participant to in person and remote study visits, and is willing to participate in the study.
  • Memory unit patients are also eligible for the study.

Study duration: Eight months and includes one in-person visit, three remote visits and daily monitoring of physical activity and sleep using a Fit-Bit device.

About the study: Unique because participants will be on study medication and placebo at separate points while in the study

Sponsor: National Institute on Aging

Summary: To determine if a study drug given as a pill can safely and effectively reduce the symptoms of agitation and aggression in people with Alzheimer's Disease.

Point of Contact: Kaitlin E. Romm, MS, VATL, ATC, Research Associate, 757.446.7406

Additional ContactGlennanCenterResearchTrials@evms.edu 

To be eligible to participate, patients must:

  • Have a diagnosis of Alzheimer’s Disease.
  • Experience frequent agitation or aggression. Common symptoms include:
    • Restlessness; pacing back and forth
    • Feeling anxious
    • Sleeplessness
    • Aggression
    • Yelling
    • Attempting to hit or kick
  • Have a caregiver who spends at least several hours per week with participant and supervises their care, is willing to accompany the participant to study visits, and is willing to participate in the study.

Study Duration: Six months and includes six clinic study visits and seven telephone contact visits.

Additional Information: Visit the study’s website.

Sponsor: Woolsey Pharmaceuticals, Inc. 

Study: Assess the effectiveness of oral fasudil in reducing wandering behaviors of elopement and/or getting lost in subjects with dementia.

Point of Contact: Find out how you and/or your loved one can enroll by contacting:

David Elkins, MS, Research Coordinator
elkinsde@evms.edu
757.446.5675

Who is eligible to participate? Those who are:

  • 50 to 90 years of age
  • Diagnosis of dementia of any etiology
  • Present of one or both of the following wandering behaviors:
    • Elopes (leaves a hospital without permission) or attempts to elope AND/OR
    • Gets lost or is unable to locate a specific place
  • Independently ambulatory with or without assistive devices such as canes or walkers
  • Have a caregiver who has more than 10 hours per week contact with the participant, is fluent and literate in English and is willing to accept responsibility for supervising the treatment of study drug and assessing the condition of the participant throughout the study

Study Duration: 6 months

 

Sponsor: Private donor from the Hampton Roads community

Summary: Goals are the following:

  • To identify patients with cognitive disorders and their care partners who are evaluated in the clinic and are interested in participating in research projects.
  • To establish a dataset of information about patients and care partners.
  • To provide research participation opportunities for family members of patients with dementia or other at-risk individuals. 

Point of Contact: Nicole Williams, Research Assistant, 757.446.7258

Additional ContactGlennanCenterResearchTrials@evms.edu 

To be eligible, participants must be:

  • Patients with any form of dementia of differing severity, from early to late dementia.
  • Patients with very mild memory impairment (MCI).
  • Family members of patients.
  • Healthy individuals who have noticed some subjective memory loss.
  • Healthy individuals with risk factors for developing dementia and Alzheimer’s such as:
    • Family history
    • Positive genetic predisposition
    • Cardiovascular risk factors

Sponsor: EVMS Clinical Research Grant (CRG)

Summary: To determine the effects of psychosocial education (PE) classes (provided by Alzheimer’s Association) on caregiver burden/stress.

Point of Contact: Patricia Sandoval, MPH, Research Coordinator 757.446.5675

Additional ContactGlennanCenterResearchTrials@evms.edu 

To be eligible, participants must be:

  • Caregivers of patients with Alzheimer’s dementia who feel stressed out from emotional and physical burden.
  • Available to attend one-hour meetings once per week for a total of 10 weeks, either virtually or face-to-face.

Study Duration: Group sessions are once per week either virtually or face-to-face for a total of 10 weeks.